Digital Health’s Transformative Role in Biopharma Research (mini-report)

Description

The healthcare sector is undergoing a substantial transformation driven by advancements in artificial intelligence (AI) and generative AI (GenAI). These groundbreaking technologies are reshaping drug discovery, disease diagnosis, treatment, and prevention approaches. To keep pace with these innovations in precision medicine and drug discovery, pharmaceutical firms are increasingly partnering with research solution providers. In this report, Galen Growth presents our latest insights into how Digital Health can utilize technology to revolutionize biopharma research, highlighting its transformative role.

Key Insights

  • The landscape of partnerships between biopharma and Digital Health underwent a significant transformation in 2020, marking a pivotal shift in focus. Notably, 36% of Biopharma partnerships announced in 2022 were specifically tailored towards providing solutions for advancing Biopharma research, signifying a strategic redirection within the industry.
  • Over the past half-decade, Oncology has risen as the foremost therapeutic area for ventures aligning with biopharma companies. This substantial trend underscores the growing synergy between these sectors and the critical emphasis placed on advancing cancer research and treatment through collaborative efforts.
  • Research Solutions, encompassing domains such as Drug Discovery, Omics-related Research, and Bioinformatics, stands out prominently. This cluster reigns as the preferred domain for collaborations between Digital Health ventures employing GenAI and Biopharma companies. The convergence of innovative technologies and specialized research solutions highlights the critical role of GenAI in reshaping biopharma research landscapes, fostering advancements in precision medicine, and propelling novel therapeutic developments.

This Global Digital Health Innovation Thematic Report on Generative AI in Digital Health includes data on the following companies:

HealthTech Alpha, a Galen Growth proprietary solution, and the global leading Digital Health private market data, intel and insights platform powers this report!

Missed our last report?

Get access to HealthTech Alpha and read our Generative AI in Digital Health – Hype or Reality?

About our Premium Reports

Our Premium Reports are specialized reports that are only available to active users with HealthTech Alpha Pro and HealthTech Alpha Enterprise accounts and are provided at no additional cost.

Source of Data

Galen Growth’s proprietary platform, HealthTech Alpha, provides the data source for this report. Corporate Business Development, Business Intelligence, and Digital Health Partnership teams worldwide prefer HealthTech Alpha, the world’s most-trusted Digital Health data, intel, and insights platform. Visit https://www.healthtechalpha.com to learn more about our data or https://www.galengrowth.com research for our reports.

Our Mission

Founded in 2016 by Digital Health experts, Galen Growth empowers global Fortune 500 companies, institutional investors, and promising Digital Health ventures to fast track their digital health strategy to create significant financial and social values. To find out more, visit https://www.galengrowth.com

About Galen Growth: 1 page
Digital Health in Biopharma Research: 9 pages, 9 charts, 1 table
Key Information

Free

BASIC

  • Download the report headlines
  • Access to limited data in HealthTech Alpha
Free
View
Recommended

PRO

  • Sign up now to download all premium research
  • Access and download all data in HealthTech Alpha
$ 385 /Month
Pro
Custom Solution

Enterprise

  • Get full access to unmatched premium research for your organization
  • Additional collaboration features to take your team's research and collaboration to the next level
Let's Talk
Contact Us

© Galen Growth 2024

Overview

Category

Stage

Total Funding

GGA Score

powered by